Trophos and the MitoTarget Consortium Demonstrate Potential of Modulating Mitochondrial Dysfunction in the Treatment of Neurodegenerative Diseases

Trophos and their collaborators in the MitoTarget Consortium present recent findings that advocate targeting mitochondrial dysfunction to treat a variety of neurodegenerative diseases. Trophos’ lead ALS therapeutic, olesoxime, is a putative modulator of the mitochondrial permeability transition pore complex, which is believed to mediate the drug’s ability to inhibit apoptotic neuronal degeneration. Olesoxime is currently in an ALS Phase III clinical trial.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail